Skip to main content

Advertisement

SpringerLink
Log in

Clinical Outcome after Selective Treatment of Patients Diagnosed with Ductal Carcinoma In Situ of the Breast

  • Breast Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

The effect of treatment of patients diagnosed with ductal carcinoma in situ (DCIS) of the breast was evaluated, and factors associated with local recurrence were assessed.

Methods

The study involved 504 patients treated by means of wide local excision alone (WLE) (n = 91), wide local excision and radiotherapy (WLE+RT) (n = 119), or mastectomy (n = 294) at the Netherlands Cancer Institute between 1986 and 2005. Clinical, pathological, and follow-up data were evaluated.

Results

The median time to follow-up was 6.7 years. The 8-year overall local recurrence rate was 12% after breast-conserving treatment (BCT) [15.6% after WLE and 8.8% after WLE+RT (P = 0.161)] and 0.9% after mastectomy (P < 0.0001). In total, 18 (66.7%) invasive local recurrences and 9 (33.3%) DCIS local recurrences occurred. The 8-year distant metastasis rate was 4% after BCT [4.3% after WLE and 4.2% after WLE+RT (P = 0.983)] and 0.9% after mastectomy (P = 0.048). Median tumor extent was 10, 15, and 35 mm for patients treated with WLE, WLE+RT, and mastectomy, respectively. Margins were involved in 6.4% of all patients. Factors associated with local recurrence were age younger than 40 years (HR 8.66), surgical margin involvement (HR 5.75), WLE (HR 26.77), and WLE+RT (HR 7.42).

Conclusion

BCT of DCIS bears the risk of residual disease progressing into invasive local recurrence and distant metastasis. A re-excision or mastectomy is therefore desired in all patients with unclear margins. Mastectomy treatment is associated with optimal local control and might be considered for patients younger than 40 years who are at high risk of local recurrence.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

FIG. 1.

Similar content being viewed by others

References

  1. Ernster VL, Ballard-Barbash R, Barlow WE, et al. Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst 2002; 94:1546–54

    PubMed  Google Scholar 

  2. Sanders ME, Schuyler PA, Dupont WD, et al. The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. Cancer 2005; 103:2481–4

    Article  PubMed  Google Scholar 

  3. Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002; 347:1233–41

    Article  PubMed  Google Scholar 

  4. Bijker N, Meijnen P, Peterse JL, et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853–a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol 2006; 24:3381–7

    Article  PubMed  Google Scholar 

  5. Fisher B, Land S, Mamounas E, et al. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the national surgical adjuvant breast and bowel project experience. Semin Oncol 2001; 28:400–18

    Article  PubMed  CAS  Google Scholar 

  6. Warnberg F, Bergh J, Zack M, et al. Risk factors for subsequent invasive breast cancer and breast cancer death after ductal carcinoma in situ: a population-based case-control study in Sweden. Cancer Epidemiol Biomarkers Prev 2001; 10:495–9

    PubMed  CAS  Google Scholar 

  7. Holland R, Peterse JL, Millis RR, et al. Ductal carcinoma in situ: a proposal for a new classification. Semin Diagn Pathol 1994; 11:167–80

    PubMed  CAS  Google Scholar 

  8. Bijker N, Peterse JL, Fentiman IS, et al. Effects of patient selection on the applicability of results from a randomised clinical trial (EORTC 10853) investigating breast-conserving therapy for DCIS. Br J Cancer 2002; 87:615–20

    Article  PubMed  CAS  Google Scholar 

  9. Houghton J, George WD, Cuzick J, et al. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet 2003; 362:95–102

    Article  PubMed  Google Scholar 

  10. Bijker N, Peterse JL, Duchateau L, et al. Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853. J Clin Oncol 2001; 19:2263–71

    PubMed  CAS  Google Scholar 

  11. Hird RB, Chang A, Cimmino V, et al. Impact of estrogen receptor expression and other clinicopathologic features on tamoxifen use in ductal carcinoma in situ. Cancer 2006; 106:2113–8

    Article  PubMed  CAS  Google Scholar 

  12. Bartelink H, Horiot JC, Poortmans P, et al. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med 2001; 345:1378–87

    Article  PubMed  CAS  Google Scholar 

  13. Cutuli B, Cohen-Solal-Le Nir C, De Lafontan B, et al. Breast-conserving therapy for ductal carcinoma in situ of the breast: the French Cancer Centers’ experience. Int J Radiat Oncol Biol Phys 2002; 53:868–79

    PubMed  Google Scholar 

  14. Solin LJ, Fourquet A, Vicini FA, et al. Long-term outcome after breast-conservation treatment with radiation for mammographically detected ductal carcinoma in situ of the breast. Cancer 2005; 103:1137–46

    Article  PubMed  Google Scholar 

  15. Omlin A, Amichetti M, Azria D, et al. Boost radiotherapy in young women with ductal carcinoma in situ: a multicentre, retrospective study of the Rare Cancer Network. Lancet Oncol 2006; 7:652–6

    Article  PubMed  Google Scholar 

  16. Vargas C, Kestin L, Go N, et al. Factors associated with local recurrence and cause-specific survival in patients with ductal carcinoma in situ of the breast treated with breast-conserving therapy or mastectomy. Int J Radiat Oncol Biol Phys 2005; 63:1514–21

    Article  PubMed  Google Scholar 

  17. Rodrigues NA, Dillon D, Carter D, et al. Differences in the pathologic and molecular features of intraductal breast carcinoma between younger and older women. Cancer 2003; 97:1393–403

    Article  PubMed  Google Scholar 

  18. Vapiwala N, Harris E, Hwang WT, et al. Long-term outcome for mammographically detected ductal carcinoma in situ managed with breast conservation treatment: prognostic significance of reexcision. Cancer J 2006; 12:25–32

    Article  PubMed  Google Scholar 

  19. Julien JP, Bijker N, Fentiman IS, et al. Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853. EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. Lancet 2000; 355:528–33

    Article  PubMed  CAS  Google Scholar 

  20. Eusebi V, Mignani S, Koerner F, et al. Well differentiated clinging carcinoma and atypical ductal hyperplasia are synonymous. Breast Cancer 2001; 8:283–4

    Article  PubMed  CAS  Google Scholar 

  21. Moinfar F, Man YG, Bratthauer GL, et al. Genetic abnormalities in mammary ductal intraepithelial neoplasia-flat type (“clinging ductal carcinoma in situ”): a simulator of normal mammary epithelium. Cancer 2000; 88:2072–81

    Article  PubMed  CAS  Google Scholar 

  22. WHO. Tumours of the breast. In: Tavassoli FA, Devilee P (eds). World Health Organization Classification of Tumours. Pathology and genetics of tumours of the breast and female genital organs. IARC Press, Lyon. 2003, pp 9–110

    Google Scholar 

  23. Wong JS, Kaelin CM, Troyan SL, et al. Prospective study of wide excision alone for ductal carcinoma in situ of the breast. J Clin Oncol 2006; 24:1031–6

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Ninja Antonini for assistance with the statistical analysis and Bin B.R. Kroon for the valuable comments.

Author information

Authors and Affiliations

  1. Department of Surgery, The Netherlands Cancer Institute—Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands

    Philip Meijnen MD, PhD, Hester S. A. Oldenburg MD, PhD & Emiel J. Th. Rutgers MD, PhD

  2. Department of Pathology, The Netherlands Cancer Institute—Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands

    Johannes L. Peterse MD

  3. Department of Radiation Oncology, The Netherlands Cancer Institute—Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands

    Harry Bartelink MD, PhD

Authors
  1. Philip Meijnen MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hester S. A. Oldenburg MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Johannes L. Peterse MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Emiel J. Th. Rutgers MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Philip Meijnen MD, PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Meijnen, P., Oldenburg, H.S.A., Peterse, J.L. et al. Clinical Outcome after Selective Treatment of Patients Diagnosed with Ductal Carcinoma In Situ of the Breast. Ann Surg Oncol 15, 235–243 (2008). https://doi.org/10.1245/s10434-007-9659-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-007-9659-2

Keywords

Search

Navigation